See more : Basin Energy Limited (BSN.AX) Income Statement Analysis – Financial Results
Complete financial analysis of CymaBay Therapeutics, Inc. (0I5P.L) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CymaBay Therapeutics, Inc., a leading company in the Medical – Pharmaceuticals industry within the Healthcare sector.
- CERo Therapeutics Holdings, Inc. (CERO) Income Statement Analysis – Financial Results
- Azelio AB (publ) (AZLOF) Income Statement Analysis – Financial Results
- HELLA GmbH & Co. KGaA (HLE.SW) Income Statement Analysis – Financial Results
- CSSC Science& Technology Co., Ltd (600072.SS) Income Statement Analysis – Financial Results
- CNOOC Limited (CEO) Income Statement Analysis – Financial Results
CymaBay Therapeutics, Inc. (0I5P.L)
About CymaBay Therapeutics, Inc.
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis (PBC), as well as has completed Phase 2b clinical study to treat patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 31.07M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.00M | 0.00 | 0.00 | 0.00 | 0.00 | 3.05M |
| Cost of Revenue | 681.00K | 710.00K | 688.00K | 632.00K | 800.00K | 43.75M | 12.00M | 9.75M | 11.70M | 11.62M | 1.17M | 3.92M |
| Gross Profit | 30.39M | -710.00K | -688.00K | -632.00K | -800.00K | -43.75M | -2.00M | -9.75M | -11.70M | -11.62M | -1.17M | -869.00K |
| Gross Profit Ratio | 97.81% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -20.04% | 0.00% | 0.00% | 0.00% | 0.00% | -28.49% |
| Research & Development | 80.12M | 67.29M | 64.54M | 35.88M | 83.84M | 58.12M | 18.94M | 15.94M | 17.03M | 15.82M | 4.53M | 9.28M |
| General & Administrative | 0.00 | 25.12M | 23.04M | 16.72M | 19.24M | 14.38M | 12.39M | 9.65M | 8.87M | 8.19M | 4.87M | 4.21M |
| Selling & Marketing | 0.00 | 0.00 | -688.00K | 73.00K | -800.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 51.95M | 25.12M | 22.35M | 16.79M | 18.44M | 14.38M | 12.39M | 9.65M | 8.87M | 8.19M | 4.87M | 4.21M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 132.07M | 92.40M | 86.89M | 52.68M | 102.28M | 32.45M | 25.09M | 15.76M | 3.08M | 19.61M | 8.09M | 9.57M |
| Cost & Expenses | 132.75M | 93.11M | 87.58M | 53.31M | 103.08M | 76.20M | 37.10M | 25.51M | 14.78M | 31.24M | 9.26M | 13.49M |
| Interest Income | 13.49M | 2.02M | 167.00K | 1.62M | 5.34M | 3.65M | 459.00K | 1.16M | 753.00K | 681.00K | 812.00K | 819.00K |
| Interest Expense | 18.95M | 14.91M | 2.58M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 681.00K | 710.00K | 688.00K | 632.00K | 572.00K | 105.00K | 35.00K | 29.00K | 22.00K | 18.00K | 55.00K | 119.00K |
| EBITDA | -101.00M | -92.40M | -86.89M | -52.68M | -102.28M | -72.40M | -21.29M | -25.56M | -25.88M | -23.99M | -9.34M | -10.32M |
| EBITDA Ratio | -325.03% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -212.90% | 0.00% | 0.00% | 0.00% | 0.00% | -338.33% |
| Operating Income | -101.68M | -93.11M | -87.58M | -53.31M | -103.08M | -72.51M | -21.33M | -25.59M | -25.90M | -24.01M | -9.40M | -10.44M |
| Operating Income Ratio | -327.23% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -213.25% | 0.00% | 0.00% | 0.00% | 0.00% | -342.23% |
| Total Other Income/Expenses | -3.69M | -12.89M | -2.42M | 2.32M | 267.00K | -43.00K | -6.23M | -1.09M | 10.37M | -7.91M | -677.00K | -817.00K |
| Income Before Tax | -105.37M | -106.00M | -90.00M | -50.99M | -102.81M | -72.55M | -27.56M | -26.67M | -15.53M | -31.92M | -10.07M | -11.26M |
| Income Before Tax Ratio | -339.10% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -275.57% | 0.00% | 0.00% | 0.00% | 0.00% | -369.02% |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -254.07M | 12.64M |
| Net Income | -105.37M | -106.00M | -90.00M | -50.99M | -102.81M | -72.55M | -27.56M | -26.67M | -15.53M | -31.92M | 243.99M | -23.90M |
| Net Income Ratio | -339.10% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -275.57% | 0.00% | 0.00% | 0.00% | 0.00% | -783.57% |
| EPS | -0.99 | -1.21 | -1.27 | -0.74 | -1.53 | -1.25 | -0.79 | -1.14 | -0.83 | -2.65 | 3.54 | 0.00 |
| EPS Diluted | -0.99 | -1.21 | -1.27 | -0.74 | -1.53 | -1.25 | -0.79 | -1.14 | -0.82 | -2.65 | 85.74 | 0.00 |
| Weighted Avg Shares Out | 106.20M | 87.80M | 71.06M | 68.89M | 67.03M | 57.81M | 34.88M | 23.40M | 18.80M | 12.04M | 68.93M | 0.00 |
| Weighted Avg Shares Out (Dil) | 106.20M | 87.80M | 71.06M | 68.89M | 67.03M | 57.84M | 34.90M | 23.45M | 18.92M | 12.05M | 2.85M | 0.00 |
Source: https://incomestatements.info
Category: Stock Reports